nsclc kras g12c

Keyword Analysis

Keyword	CPC	PCC	Volume	Score	Length of keyword
nsclc kras g12c	1.73	0.6	4264	77	15
nsclc	0.39	0.4	112	47	5
kras	0.19	0.5	974	51	4
g12c	0.03	0.9	6657	3	4

Keyword	CPC	PCC	Volume	Score
nsclc kras g12c	0.79	0.9	881	47
nsclc kras g12c treatment	0.14	0.4	1635	4
kras g12c mutation nsclc	1.91	0.3	6981	88
prevalence of kras g12c in nsclc	1.72	1	7987	21
kras g12c-mutated nsclc	0.09	0.6	9054	92
kras g12c mutation treatment	0.99	0.7	9823	86
kras g12c lung cancer treatment	1.78	0.7	2941	91
kras mutation nsclc treatment	0.27	0.9	4389	69
kras g12c clinical trial	0.82	0.7	6783	89
kras g12c mutation lung cancer treatment	1.11	0.4	3057	96
kras g12v mcrc treatment options	1.99	0.1	6872	92
kras g12c on inhibitor	0.11	0.8	2598	19
kras g12c inhibitor clinical trial	0.55	0.5	1163	67
non-small cell lung cancer kras g12c therapy	1.05	0.5	2952	71
kras g12c inhibitor-12	0.41	0.3	8238	49
kras g12c inhibitor drugs	1.14	0.1	1783	35
kras g12c inhibitor 1	1.68	0.3	506	7
kras g12c inhibitor fda approval	1.75	0.6	3735	13
kras g12v mutation treatment	0.37	0.9	7185	25
kras g12c lung cancer	1.85	0.1	7944	88
fda approved kras g12c inhibitor	0.94	1	7609	17
kras g12d mutation treatment	0.05	0.1	3951	16
kras g12c cell line	0.29	0.5	2203	88
kras g12c inhibitor sotorasib	0.02	0.1	591	69
kras g12v clinical trial	1.43	0.5	4743	96
treatments specifically for kras 12gv crc	0.04	1	977	54
kras-g12c	0.07	1	5660	91